Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Menopause. 2013 Jun;20(6):695–709. doi: 10.1097/GME.0b013e3182960cf8

TABLE 3.

Randomized, placebo-controlled trials of estrogen alone on verbal memory in older postmenopausal women

Author N (All)
Final
ET/PL
Mean
Age
(SD or
span)
Prior
HT Use
(%)
Menopausal Status/
Menopausal Symptoms/
Years since Menopausea
Design Duration HT Dose Test Results
Wolf (1999) (40)
38
21/17
68.7
(5.8)
? Postmenopausal, 13
Hysterectomy (8 with
BSO)/ Unknown / 17 y
Parallel;
2 groups
2 wk Trans
E2
0.1 mg/d Word pair
recall
ET=PL
Yaffe (2006) (417)
376
191/
185
66.7
(5.0)
? Postmenopausal/16%/
≥ 5 y
Parallel;
2 groups
24 m Trans
E2
0.014
mg/d
Paragraph
Recall,
CERAD
Word List
ET=PL
Almeida (2006) (115)
86
47/39
73.7
(3.8)
38% Postmenopausal/
16%/28.7 y
Parallel;
2 groups
20 wk Oral
E2
2 mg/d CVLT ET=PL
Pefanco (2007) (57)
45
(32)/(25)a
75.5
(5.1)
? Postmenopausal, 32%
had hysterectomy /
Unknown
Parallel;
2 groups
36 m Trans
E2
0.25
mg/d
Paired
Associates
Logical
Memory
ET=PL
Resnick (2009) (886)
752
370/382
74.0
(3.8)
48% Postmenopausal with
prior hysterectomy/ 9%
/Unknown
Parallel;
2 groups
5.7 y a CEE 0.625
mg/d
CVLT ET=PL
a

Notes: On average women were tested at the initial cognitive assessment 3 years after randomization in the WHI. The average follow-up after that initial assessment was 2.7 years. Abbreviations: BSO= bilateral salpingo-oopherectomy; CERAD = Consortium to Establish a Registry for Alzheimer’s Disease; CVLT= California Verbal Learning Test; E2 = Estradiol; ET= Estrogen therapy; HT = Hormone Therapy; PL = Placebo; Trans = transdermal.